{"entity":{"id":"nct05802225","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","aka":[],"tldr":"A phase 3 trial of Pertuzumab in HER2-positive breast cancer, run by Biocad, active and no longer recruiting.","summary":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT05802225 by Biocad, with 398 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2025-06-06. Interventions recorded: BCD-178 and Perjeta.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05802225","url":"https://clinicaltrials.gov/study/NCT05802225"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["pertuzumab"],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05802225","phase":"3","setting":"A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","sponsor":"Biocad","enrolled":398,"outcomes":[]},"route":"/trials/nct05802225/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}]}}